|
Hypertensive disease
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Then, an in vitro study of hypertension due to rotational force was conducted, and an increase in fibrosis markers and decrease in KLF15 levels were determined after application of 4 mmHg pressure in primary cultured human podocytes.
|
31697927 |
2020 |
|
Colorectal Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
LncRNA TTN-AS1 sponges miR-376a-3p to promote colorectal cancer progression via upregulating KLF15.
|
31610194 |
2020 |
|
Acute Promyelocytic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Expression of four Krüppel-like transcription factors (KLF), KLF4, KLF6, PLZF (promyelocytic leukemia zinc finger), and KLF15, are induced in TG neurons early during dexamethasone-induced reactivation.
|
31776270 |
2020 |
|
hypertensive nephropathy
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
First, we found that KLF15 expression was decreased in patients with hypertensive nephropathy.
|
31697927 |
2020 |
|
Tumor Cell Invasion
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
In conclusions, TTN-AS1 promoted CRC proliferation and invasion through miR-376a-3p/KLF15 axis.
|
31610194 |
2020 |
|
Promyelocytic leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Expression of four Krüppel-like transcription factors (KLF), KLF4, KLF6, PLZF (promyelocytic leukemia zinc finger), and KLF15, are induced in TG neurons early during dexamethasone-induced reactivation.
|
31776270 |
2020 |
|
Malignant neoplasm of colon and/or rectum
|
0.010 |
Biomarker
|
disease |
BEFREE |
LncRNA TTN-AS1 sponges miR-376a-3p to promote colorectal cancer progression via upregulating KLF15.
|
31610194 |
2020 |
|
Congestive heart failure
|
0.070 |
Biomarker
|
disease |
BEFREE |
KLF15 may therefore be an effective therapeutic target for the treatment of heart failure and other cardiovascular diseases.
|
30831134 |
2019 |
|
Heart failure
|
0.060 |
Biomarker
|
disease |
BEFREE |
KLF15 may therefore be an effective therapeutic target for the treatment of heart failure and other cardiovascular diseases.
|
30831134 |
2019 |
|
Hypertensive disease
|
0.040 |
Biomarker
|
group |
BEFREE |
miR-190a-5p participates in the regulation of hypoxia-induced pulmonary hypertension by targeting KLF15 and can serve as a biomarker of diagnosis and prognosis in chronic obstructive pulmonary disease complicated with pulmonary hypertension.
|
30538440 |
2019 |
|
Cardiovascular Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
KLF15 may therefore be an effective therapeutic target for the treatment of heart failure and other cardiovascular diseases.
|
30831134 |
2019 |
|
Kidney Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
Krüppel-like Factor 15: A Potential Therapeutic Target For Kidney Disease.
|
31523196 |
2019 |
|
Renal fibrosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Loss of KLF4 and KLF15 promotes renal fibrosis, while fibrotic kidneys have increased KLF5 and KLF6 expression.
|
30662001 |
2019 |
|
Coronary Arteriosclerosis
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, we identify EZH2 as an epigenetic regulator of KLF15 along with DNA hypermethylation, and we propose a novel mechanism through which coronary heart disease reprograms the expression of both intermediate enzymes and upstream regulators of cardiac metabolism such as KLF15.
|
30089854 |
2019 |
|
Coronary Arteriosclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Transcriptomic bioinformatics, phenotyping of Klf15 knockout mice, Wnt-signaling-modulated hearts, and pressure overload and myocardial ischemia models were applied.
|
31582141 |
2019 |
|
Diabetic Nephropathy
|
0.020 |
Biomarker
|
disease |
BEFREE |
In conclusion, Jun, Ptgs2, Fn1, Cdk2, Fos, Hspa5, Hsp90b1, Hyou1, RHOB, CFH and KLF15 may be potential therapeutic targets for mesangial cells associated with DN, which may provide insight into DN treatment strategies.
|
31105790 |
2019 |
|
Vascular inflammations
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Similarly, perivascularly overexpression of KLF15 but not KLF15-ΔTAD in carotid arteries also attenuated Ang II-induced vascular inflammation and fibrosis.
|
30776250 |
2019 |
|
Chronic Kidney Diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
In this review, we discuss recent advances and update our overview of the functions of KLF15 in kidney biology, hoping to provide new perspectives on the progression and therapy of Chronic Kidney Disease (CKD).
|
31523196 |
2019 |
|
Coronary heart disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, we identify EZH2 as an epigenetic regulator of KLF15 along with DNA hypermethylation, and we propose a novel mechanism through which coronary heart disease reprograms the expression of both intermediate enzymes and upstream regulators of cardiac metabolism such as KLF15.
|
30089854 |
2019 |
|
Hyperglycemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Hyperglycemia was found to upregulate the KLF15 protein in skeletal muscle of diabetic animals, which is achieved via downregulation of the E3 ubiquitin ligase WWP1 and consequent suppression of the ubiquitin-dependent degradation of KLF15.
|
30830866 |
2019 |
|
Chronic Obstructive Airway Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
miR-190a-5p participates in the regulation of hypoxia-induced pulmonary hypertension by targeting KLF15 and can serve as a biomarker of diagnosis and prognosis in chronic obstructive pulmonary disease complicated with pulmonary hypertension.
|
30538440 |
2019 |
|
Myocardial Ischemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Transcriptomic bioinformatics, phenotyping of Klf15 knockout mice, Wnt-signaling-modulated hearts, and pressure overload and myocardial ischemia models were applied.
|
31582141 |
2019 |
|
End stage cardiac failure
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
This study aimed to characterize the impact of KLF15-dependent cardiac transcriptional networks leading to HF progression, amenable to therapeutic intervention in the adult heart.
|
31582141 |
2019 |
|
Coronary Artery Disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, we identify EZH2 as an epigenetic regulator of KLF15 along with DNA hypermethylation, and we propose a novel mechanism through which coronary heart disease reprograms the expression of both intermediate enzymes and upstream regulators of cardiac metabolism such as KLF15.
|
30089854 |
2019 |
|
Congestive heart failure
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
It also discusses our recent paper that described the contribution of genetic variants in <i>KLF15</i> to the development of LVH and heart failure in high-risk patients.
|
29702551 |
2018 |